SteveGrenard
13th May 2006, 09:22 AM
Many children with learning disabilities, others labeled as having attention deficit disorder, are sometimes the victims of undiagnosed and untreated sleep disordered breathing (SDB).
SDB interferes with normal sleep leading to excessive daytime
sleepiness and all that it entails in terms of learning or otherwise normal functioning. Up to now the only "legal" treatment for kids in the U.S. was to enlarge their airways with surgery for removal of tonsils and adenoids (which can be a problem causing SDB). CPAP, which is used routinely in adults, had to be used only in children weighing over 40 kgs or prescribed off-label with informed, formal consent.
The recent epidemic of childhood obesity makes SDB worse.
Press Release
ResMed Corp ( http://www.resmed.com/ ), San Diego, announced thatthe US Food and Drug Administration (FDA) has cleared its pediatric positive airway pressure (PAP) system for domestic use. Its Mirage Kidsta nasal mask and the VPAP® III ST-A bilevel ventilator system combo was approved for
treating children 7 years and older that weigh more than 40 lbs in the hospital and home. The Mirage Kidsta is based on ResMed's Mirage mask for adults and has the same dual-wall cushion technology and design as the adult
mask. The VPAP III ST-A has been available to adult patients since 2004 and ResMed expects the Mirage Kidsta mask to ship in late summer.
"Pediatric specialists are increasingly aware of the prevalence and symptoms of sleep apnea and they recognize the need for suitable therapy options for their pediatric patients," said Rochelle Turetsky, MD, of Gaylord Hospital in Wallingford, Conn, in a statement provided by ResMed.
"As a result, pediatricians have seen an increasing and unmet need for an approved pediatric device. ResMed's recent FDA clearance of a full therapy system for pediatric use in the hospital and home is excellent news for patients and physicians and will meet a growing need in pediatric
practices."
We have already been supporting pediatric patients with the Mirage Kidsta in Canada and Latin America; now,
we have the only bilevel system FDA cleared for pediatric use in the hospital and home.
We have an extraordinary opportunity to provide a complete treatment system to a previously under-supported patient group in the United
States."
The Mirage Kidsta has been commercially available in Europe since 2004. It has been used to treat patients in Germany, France, the United Kingdom and other countries, ResMed said.
http://resmed.com/portal/site/ResMedUS/?vgnCId=a9c81cc60d8fa010VgnVCMServerc60210acRCRD&vgnChId=c8d9f66a9760ef00VgnVCMServerc60210ac____&epi_menuItemID=66a328956d1d7856796046c06c2001ca&vgnReset=1&vgnPNum=null
SDB interferes with normal sleep leading to excessive daytime
sleepiness and all that it entails in terms of learning or otherwise normal functioning. Up to now the only "legal" treatment for kids in the U.S. was to enlarge their airways with surgery for removal of tonsils and adenoids (which can be a problem causing SDB). CPAP, which is used routinely in adults, had to be used only in children weighing over 40 kgs or prescribed off-label with informed, formal consent.
The recent epidemic of childhood obesity makes SDB worse.
Press Release
ResMed Corp ( http://www.resmed.com/ ), San Diego, announced thatthe US Food and Drug Administration (FDA) has cleared its pediatric positive airway pressure (PAP) system for domestic use. Its Mirage Kidsta nasal mask and the VPAP® III ST-A bilevel ventilator system combo was approved for
treating children 7 years and older that weigh more than 40 lbs in the hospital and home. The Mirage Kidsta is based on ResMed's Mirage mask for adults and has the same dual-wall cushion technology and design as the adult
mask. The VPAP III ST-A has been available to adult patients since 2004 and ResMed expects the Mirage Kidsta mask to ship in late summer.
"Pediatric specialists are increasingly aware of the prevalence and symptoms of sleep apnea and they recognize the need for suitable therapy options for their pediatric patients," said Rochelle Turetsky, MD, of Gaylord Hospital in Wallingford, Conn, in a statement provided by ResMed.
"As a result, pediatricians have seen an increasing and unmet need for an approved pediatric device. ResMed's recent FDA clearance of a full therapy system for pediatric use in the hospital and home is excellent news for patients and physicians and will meet a growing need in pediatric
practices."
We have already been supporting pediatric patients with the Mirage Kidsta in Canada and Latin America; now,
we have the only bilevel system FDA cleared for pediatric use in the hospital and home.
We have an extraordinary opportunity to provide a complete treatment system to a previously under-supported patient group in the United
States."
The Mirage Kidsta has been commercially available in Europe since 2004. It has been used to treat patients in Germany, France, the United Kingdom and other countries, ResMed said.
http://resmed.com/portal/site/ResMedUS/?vgnCId=a9c81cc60d8fa010VgnVCMServerc60210acRCRD&vgnChId=c8d9f66a9760ef00VgnVCMServerc60210ac____&epi_menuItemID=66a328956d1d7856796046c06c2001ca&vgnReset=1&vgnPNum=null